Chemoradiotherapy in Unresectable Esophageal Cancer

This phase I/II clinical study is designed to evaluate the 1 year local tumor control rate of chemoradiotherapy using albumin-bound paclitaxel and cisplatin in unresectable esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.

Trial Details

NCT ID
NCT04278287
Phase
PHASE1 / PHASE2
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Radiotherapy
  • Albumin-Bound Paclitaxel
  • Cisplatin
Locations (sample)
  • Anyang, Henan, China|36.096,114.38278
  • Changsha, Hunan, China|28.19874,112.97087
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Nanjing, Jiangsu, China|32.06167,118.77778
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • 18\~75 years
  • Pathologically or cytologically proven unresectable esophageal squamous cell carcinomas in patients staged as T3N1M0-1b and T4N0-1M0-1b(AJCC 6th TN…
  • Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences
  • ECOG PS score: 0\~1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →